CTP 010Alternative Names: CTP-010
Latest Information Update: 27 May 2015
At a glance
- Originator Concit Pharma
- Developer Contera Pharma
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase Unknown Drug-induced dyskinesia
Most Recent Events
- 24 Apr 2013 Investigation in Drug-induced dyskinesia in Denmark (unspecified route)
- 24 Apr 2013 Concit Pharma plans a phase IIa trial for Drug-induced dyskinesia